China's Leading Drug Outfits Gear Up To Push Development Of Biologics, Biosimilars
This article was originally published in PharmAsia News
Executive Summary
BEIJING - Some of China's leading innovators in drug development are laying the groundwork to become major producers of biopharmaceuticals, including reverse-engineered biosimilars, and sales of biologics have expanded speedily over the last decade
You may also be interested in...
While Gearing Up To Supply Biosimilars To U.S. And EU Markets, Will Leading Chinese Biotech 3SBio Be M&A Target?
BEIJING - One of China's leading biopharmaceutical developers, 3SBio, reported solid earnings for the third quarter of 2010, which could help make the firm ripe for a takeover by an international player
While Gearing Up To Supply Biosimilars To U.S. And EU Markets, Will Leading Chinese Biotech 3SBio Be M&A Target?
BEIJING - One of China's leading biopharmaceutical developers, 3SBio, reported solid earnings for the third quarter of 2010, which could help make the firm ripe for a takeover by an international player